Bayer Healthcare has announced a new oncology collaboration and licensing agreement with Compugen Ltd to research and develop antibody-based therapeutics in oncology against two novel targets. The deal is valued at more than $500 million.
Bayer Healthcare has announced a new oncology collaboration and licensing agreement with Compugen Ltd to research and develop antibody-based therapeutics in oncology against two novel targets. The deal is valued at more than $500 million.